<DOC>
	<DOCNO>NCT02558231</DOCNO>
	<brief_summary>The objective clinical trial compare efficacy safety initial triple oral treatment regimen ( macitentan , tadalafil , selexipag ) versus initial dual oral treatment regimen ( macitentan , tadalafil , placebo ) newly diagnose , treatment-naïve patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>The Efficacy Safety Initial Triple Versus Initial Dual Oral Combination Therapy Patients With Newly Diagnosed Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent prior studymandated procedure . 2 . Male female ≥ 18 ≤ 75 year age screening . 3 . Initial PAH diagnosis &lt; 6 month prior enrollment . 4 . RHC perform Day −28 Day 1 , meet follow criterion : Mean pulmonary artery pressure ( mPAP ) ≥ 25 mmHg . Pulmonary artery wedge pressure leave ventricular enddiastolic pressure ≤ 15 mmHg . PVR ≥ 480 dyn•sec/cm5 ( ≥ 6 Wood Units ) . Negative vasoreactivity test mandatory idiopathic , heritable , drug/toxin induce PAH ( previous RHC ) . 5 . Symptomatic PAH belong one follow subgroup : Idiopathic . Heritable . Drug toxin induce . Associated one following : connective tissue disease ; HIV infection ; congenital heart disease . 6 . 6minute walk distance ( 6MWD ) ≥ 50 screening . 7 . Women childbearing potential must pregnant , must perform regular pregnancy test , use reliable contraception . 1 . Any PAHspecific drug therapy time . 2 . Cardio pulmonary rehabilitation program base exercise ( plan , start ≤ 12 week prior Day 1 ) . 3 . Body mass index ( BMI ) &gt; 40 kg/m2 screening . 4 . Presence three follow risk factor heart failure preserve ejection fraction screening : BMI &gt; 30 kg/m2 . Diabetes mellitus type . Essential hypertension . Coronary artery disease , i.e. , follow : History stable angina More 50 % stenosis coronary artery ( coronary angiography ) History myocardial infarction History plan coronary artery bypass graft and/or coronary artery stenting . 5 . Acute myocardial infarction ≤ 12 week prior screen . 6 . Stroke ≤ 12 week prior screen . 7 . Known permanent atrial fibrillation . 8 . SBP &lt; 90 mmHg screen Day 1 . 9 . Ongoing plan treatment organic nitrate and/or doxazosin . 10 . Presence one follow sign relevant lung disease time screening : Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % predict ( eligible mild interstitial lung disease compute tomography ) . Forced vital capacity ( FVC ) &lt; 60 % predict . Forced expiratory volume one second ( FEV1 ) &lt; 60 % predict . 11 . Known suspected pulmonary venoocclusive disease ( PVOD ) . 12 . Documented severe hepatic impairment ( without cirrhosis ) accord National Cancer Institute organ dysfunction work group criterion , define total bilirubin &gt; 3 × upper limit normal range ( ULN ) accompany aspartate aminotransferase ( AST ) &gt; ULN ( assessed central laboratory screening ) ; and/or ChildPugh Class C. 13 . Serum AST and/or alanine aminotransferase ( ALT ) &gt; 3 × ULN ( assessed central laboratory screening ) . 14 . Severe renal impairment ( estimate creatinine clearance ≤ 30 mL/min/1.73 m2 ) assess central laboratory screening . 15 . Ongoing planned dialysis . 16 . Hemoglobin &lt; 100 g/L assessed central laboratory screening . 17 . Known suspect uncontrolled thyroid disease ( hypo hyperthyroidism ) . 18 . Loss vision one eye nonarteritic ischemic optic neuropathy ( NAION ) . 19 . Treatment strong inducer cytochrome P450 3A4 ( CYP3A4 ; e.g. , carbamazepine , rifampin , rifampicin , rifabutin , rifapentin , phenobarbital , phenytoin , St. John 's wort ) ≤ 28 day prior Day 1 . 20 . Treatment strong inhibitor CYP3A4 ( e.g. , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , nefazodone , ritonavir , saquinavir ) ≤ 28 day prior Day 1 . 21 . Treatment another investigational drug ( plan , take ≤ 12 week prior Day 1 ) . 22 . Hypersensitivity 3 study treatment excipient formulation . 23 . Pregnancy , breastfeeding , intention become pregnant study . 24 . Concomitant lifethreatening disease life expectancy &lt; 12 month . 25 . Alcohol abuse . 26 . Any factor condition likely affect protocol compliance subject , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>